Cyclopharm Limited (ASX:CYC)

James McBrayer
Market Cap (AUD): 122.32M
Sector: Health Care
Last Trade (AUD): 1.31 +0 (+0%)
Tab Bar

1. About

Cyclopharm Limited (ASX:CYC) is a radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. 

Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas used in functional lung ventilation imaging.  


The Technegas technology is a structured ultrafine dispersion of radioactive labelled carbon, produced by using dried Technetium99m in a carbon crucible, micro furnaced for a few seconds at around 2,700o C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. 

Historically used in the diagnosis of pulmonary embolism, Technegas, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.  


Cyclopharm's patented nuclear medicine technology Ultralute, extends the useful life of Molybdenum99 (Mo99) generators by up to 50%. This technology potentially gives nuclear medicine departments the ability to dramatically improve operating efficiencies and health outcomes for patients. Mo99 generators are used in diagnostic imaging to harvest Technetium99m, or Tc99m, which is the primary isotope used in diagnostic imaging throughout the world. This isotope accounts for approximately 80% of all nuclear medicine diagnostic imaging procedures

2. Business model

3. Strategy

4. Markets

5. Competition

6. History

7. Team

8. Financials

9. Risk